Loading cancer entity…
Loading cancer entity…
Clinical trials
136 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01445288 | Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | completed | — | 76 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03251989 | Rare CNS Tumors Outcomes &Risk | completed | — | 326 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03389802 | Phase I Study of APX005M in Pediatric Central Nervous System Tumors | completed | Phase 1 | 32 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03900689 | Social Determinants of Health in Glioblastoma Population | completed | — | 100 | Wake Forest University Health SciencesOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03194906 | Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors | completed | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT01096368 | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma | completed | Phase 3 | 479 | Children's Oncology GroupNETWORK | 4 | Apr 30, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03638167 | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | completed | Phase 1 | 11 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT02238899 | Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma | completed | — | 354 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT01165632 | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma | completed | Early Phase 1 | 24 | Mayo ClinicOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT01295944 | Carboplatin and Bevacizumab for Recurrent Ependymoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2025 | clinicaltrials |
| NCT03128047 | HUMC 1612: Optune NovoTTF-200A System | completed | Phase 1 | 7 | Hackensack Meridian HealthOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT01288235 | Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation | completed | Phase 2 | 100 | Massachusetts General HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03572530 | Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma(5-AZA) | completed | Phase 1 | 3 | The University of Texas Health Science Center, HoustonOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT03434262 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | completed | Phase 1 | 68 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT02155920 | Everolimus for Children With Recurrent or Progressive Ependymoma | completed | Phase 2 | 11 | University of Texas Southwestern Medical CenterOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT03043391 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | completed | Phase 1 | 8 | Istari Oncology, Inc.INDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03206021 | COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors(COZMOS) | completed | Phase 1 | 31 | The Hospital for Sick ChildrenOTHER | 3 | Apr 5, 2024 | clinicaltrials |
| NCT04408092 | Study of the Effect of GM-CSF on Macrophages in Ependymoma | completed | Early Phase 1 | 6 | University of Colorado, DenverOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT00019578 | Stereotactic Radiosurgery in Treating Patients With Brain Tumors | completed | Phase 1 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT00634231 | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors | completed | Phase 1 | 8 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT03860376 | Ex Vivo Drug Sensitivity Testing and Mutation Profiling | completed | — | 25 | Florida International UniversityOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT02013297 | Study of SBRT Efficacy on Intra and Extra -Cranial Tumors or Metastasis in Pediatrics Population (SBRT Pediatrics)(SBRT) | completed | N/A | 61 | Centre Leon BerardOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03387020 | Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors | completed | Phase 1 | 22 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 27, 2021 | clinicaltrials |
| NCT01125046 | Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | completed | Phase 2 | 50 | Northwestern UniversityOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01024907 | Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas | completed | Phase 1 / Phase 2 | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02271711 | Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors | completed | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT02502708 | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | completed | Phase 1 | 81 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 4, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT00994071 | A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00749723 | Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children(HIT-REZ-2005) | completed | Phase 2 / Phase 3 | 174 | University Hospital, BonnOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00919750 | Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors | completed | — | 1,258 | Children's Oncology GroupNETWORK | 6 | Jul 16, 2018 | clinicaltrials |
| NCT01171469 | Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | completed | Phase 1 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | completed | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2017 | clinicaltrials |
| NCT01407744 | Study of Tumor Samples From Patients With Ependymoma Treated on the Children's Oncology Group ACNS0121 Trial | completed | — | 80 | Children's Oncology GroupNETWORK | 1 | May 18, 2016 | clinicaltrials |
| NCT00326664 | AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2016 | clinicaltrials |
| NCT01498783 | Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma(SJREFU) | completed | Phase 1 | 26 | St. Jude Children's Research HospitalOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT01119599 | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2015 | clinicaltrials |
| NCT01462695 | Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 3 | Aug 27, 2015 | clinicaltrials |
| NCT00946335 | ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors | completed | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2014 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00052780 | Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors | completed | Phase 1 | 72 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00063973 | Cilengitide in Treating Children With Refractory Primary Brain Tumors | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials